Peer-influenced content. Sources you trust. No registration required. This is HCN.

ASCO 2020: May 31 Highlights

Day two of ASCO 2020 featured late-breaking data from a phase 3 trial evaluating early local therapy in metastatic breast cancer, as well as results of the phase 3 ENDURANCE trial, the ALPHA CAR T-cell trial, and the C-144-01 trial assessing TIL therapy.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form